DE69919212T2
(de)
*
|
1998-12-23 |
2005-07-28 |
Eli Lilly And Co., Indianapolis |
Aromatische amiden
|
DE10023484A1
(de)
|
2000-05-09 |
2001-11-22 |
Schering Ag |
Anthranylamide und deren Verwendung als Arzneimittel
|
DE10023485A1
(de)
*
|
2000-05-09 |
2001-11-22 |
Schering Ag |
Anthranylalkyl- und -cycloalkylamide und deren Verwendung als Arzneimittel
|
DE10023486C1
(de)
|
2000-05-09 |
2002-03-14 |
Schering Ag |
Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel
|
ES2299504T3
(es)
|
2000-06-21 |
2008-06-01 |
F. Hoffmann-La Roche Ag |
Derivados de benzotiazol para el tratamiento de la enfermedad de alzheimer y de la enfermedad de parkinson.
|
AU3950802A
(en)
|
2000-12-07 |
2002-06-18 |
Cv Therapeutics Inc |
Abca-1 elevating compounds
|
US7105682B2
(en)
|
2001-01-12 |
2006-09-12 |
Amgen Inc. |
Substituted amine derivatives and methods of use
|
US6878714B2
(en)
|
2001-01-12 |
2005-04-12 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
US20020147198A1
(en)
*
|
2001-01-12 |
2002-10-10 |
Guoqing Chen |
Substituted arylamine derivatives and methods of use
|
US20030134836A1
(en)
|
2001-01-12 |
2003-07-17 |
Amgen Inc. |
Substituted arylamine derivatives and methods of use
|
US6995162B2
(en)
*
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
US7102009B2
(en)
|
2001-01-12 |
2006-09-05 |
Amgen Inc. |
Substituted amine derivatives and methods of use
|
SI3351246T1
(sl)
|
2001-02-19 |
2019-08-30 |
Novartis Pharma Ag |
Derivat rapamicina za zdravljenje trdnega tumorja, povezanega z deregulirano angiogenezo
|
US6864255B2
(en)
|
2001-04-11 |
2005-03-08 |
Amgen Inc. |
Substituted triazinyl amide derivatives and methods of use
|
DE10123587B4
(de)
*
|
2001-05-08 |
2005-04-07 |
Schering Ag |
Cyanoanthranylamid-Derivate und deren Verwendung als Arzneimittel
|
US7429592B2
(en)
|
2001-05-08 |
2008-09-30 |
Schering Aktienegesellschaft |
Cyanoanthranilamide derivatives and the use thereof as medicaments
|
CN1518546A
(zh)
*
|
2001-05-08 |
2004-08-04 |
���ֹɷݹ�˾ |
作为vegrf-2和vegfr-3抑制剂的选择性邻氨基苯甲酰胺吡啶酰胺
|
EP1389201A1
(de)
|
2001-05-08 |
2004-02-18 |
Schering Aktiengesellschaft |
N-oxidanthranylamid-derivate und deren verwendung als arzneimittel
|
DE10123573B4
(de)
*
|
2001-05-08 |
2005-06-02 |
Schering Ag |
N-Oxidanthranylamid-Derivate und deren Verwendung als Arzneimittel
|
NZ529145A
(en)
|
2001-05-16 |
2005-07-29 |
Novartis Ag |
Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)- 2pyrimidine-amine and a chemotherapeutic agent
|
EP1403255A4
(en)
*
|
2001-06-12 |
2005-04-06 |
Sumitomo Pharma |
INHIBITORS OF RHO KINASE
|
TWI315982B
(en)
|
2001-07-19 |
2009-10-21 |
Novartis Ag |
Combinations comprising epothilones and pharmaceutical uses thereof
|
ATE511840T1
(de)
|
2001-10-09 |
2011-06-15 |
Amgen Inc |
Imidazolderivate als entzündungshemmende mittel
|
GB0126902D0
(en)
*
|
2001-11-08 |
2002-01-02 |
Novartis Ag |
Organic compounds
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
MXPA04011384A
(es)
|
2002-05-16 |
2005-02-14 |
Novartis Ag |
Uso de agentes de union del receptor edg en cancer.
|
US7307088B2
(en)
|
2002-07-09 |
2007-12-11 |
Amgen Inc. |
Substituted anthranilic amide derivatives and methods of use
|
US7094789B2
(en)
|
2002-07-22 |
2006-08-22 |
Asahi Kasei Pharma Corporation |
5-substituted isoquinoline derivatives
|
US7615565B2
(en)
|
2002-07-31 |
2009-11-10 |
Bayer Schering Pharma Aktiengesellschaft |
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
|
DE10235690A1
(de)
*
|
2002-07-31 |
2004-02-19 |
Schering Ag |
VEGFR-2 und VEGFR-3 inhibitorische Anthranylamidpyridinamide
|
US7338956B2
(en)
|
2002-08-07 |
2008-03-04 |
Sanofi-Aventis Deutschland Gmbh |
Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
|
EP1388341A1
(en)
*
|
2002-08-07 |
2004-02-11 |
Aventis Pharma Deutschland GmbH |
Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
|
ATE440827T1
(de)
*
|
2002-12-04 |
2009-09-15 |
Ore Pharmaceuticals Inc |
Melanocortin-rezeptormodulatoren
|
US7696225B2
(en)
|
2003-01-06 |
2010-04-13 |
Osi Pharmaceuticals, Inc. |
(2-carboxamido)(3-Amino) thiophene compounds
|
TWI299664B
(en)
|
2003-01-06 |
2008-08-11 |
Osi Pharm Inc |
(2-carboxamido)(3-amino)thiophene compounds
|
US7087761B2
(en)
|
2003-01-07 |
2006-08-08 |
Hoffmann-La Roche Inc. |
Cyclization process for substituted benzothiazole derivatives
|
CA2514940A1
(en)
|
2003-02-03 |
2004-08-19 |
Janssen Pharmaceutica N.V. |
Quinoline-derived amide modulators of vanilloid vr1 receptor
|
WO2004072069A1
(en)
*
|
2003-02-14 |
2004-08-26 |
Glaxo Group Limited |
Carboxamide derivatives
|
TWI369353B
(en)
|
2003-03-07 |
2012-08-01 |
Santen Pharmaceutical Co Ltd |
Novel compound having 4-pyridylalkylthio group as substituent
|
MXPA05012461A
(es)
|
2003-05-19 |
2006-02-22 |
Irm Llc |
Compuestos y composiciones inmunosupresores.
|
MY150088A
(en)
|
2003-05-19 |
2013-11-29 |
Irm Llc |
Immunosuppressant compounds and compositions
|
JP2006526660A
(ja)
*
|
2003-06-05 |
2006-11-24 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Vr1レセプターのモジュレーター
|
US7202260B2
(en)
*
|
2003-06-13 |
2007-04-10 |
Schering Ag |
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones
|
DE10327719A1
(de)
*
|
2003-06-13 |
2005-01-20 |
Schering Ag |
VEGFR-2 und VEGFR-3 Inhibitorische Anthranylamidpyridone
|
WO2006074147A2
(en)
|
2005-01-03 |
2006-07-13 |
Myriad Genetics, Inc. |
Nitrogen containing bicyclic compounds and therapeutical use thereof
|
US8309562B2
(en)
|
2003-07-03 |
2012-11-13 |
Myrexis, Inc. |
Compounds and therapeutical use thereof
|
CA2531859C
(en)
*
|
2003-07-11 |
2013-08-06 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Benzimidazole derivatives as raf kinase inhibitors
|
GB0326601D0
(en)
*
|
2003-11-14 |
2003-12-17 |
Novartis Ag |
Organic compounds
|
UA89035C2
(ru)
|
2003-12-03 |
2009-12-25 |
Лео Фарма А/С |
Эфиры гидроксамовых кислот и их фармацевтическое применение
|
WO2005085201A1
(ja)
|
2004-02-17 |
2005-09-15 |
Santen Pharmaceutical Co., Ltd. |
置換又は無置換アミノ基を導入した4-ピリジルアルキルチオ基を有する新規環式化合物
|
DE102004009238A1
(de)
*
|
2004-02-26 |
2005-09-08 |
Merck Patent Gmbh |
Arylamid-Derivate
|
EP1568368A1
(en)
*
|
2004-02-26 |
2005-08-31 |
Schering Aktiengesellschaft |
Pharmaceutical combination comprising a CDK inhibitor and a VEGF receptor inhibitor
|
WO2005085188A2
(en)
*
|
2004-03-02 |
2005-09-15 |
Compass Pharmaceuticals Llc |
Compounds and methods for anti-tumor therapy
|
US7427390B2
(en)
*
|
2004-03-10 |
2008-09-23 |
Schering Ag |
Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy
|
DE102004011720B4
(de)
*
|
2004-03-10 |
2008-04-03 |
Bayer Schering Pharma Aktiengesellschaft |
Radiohalogenierte Benzamidderivate und deren Verwendung in der Tumordiagnostik und Tumortherapie
|
DK1753760T3
(da)
|
2004-05-24 |
2008-04-14 |
Hoffmann La Roche |
4-hydroxy-4-methyl-piperidin-1-carboxylsyre-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amid
|
DE102004039876A1
(de)
*
|
2004-06-23 |
2006-01-26 |
Lanxess Deutschland Gmbh |
Herstellung von fluorierten 1,3-Benzodioxanen
|
GB0512324D0
(en)
|
2005-06-16 |
2005-07-27 |
Novartis Ag |
Organic compounds
|
WO2006032631A1
(en)
*
|
2004-09-22 |
2006-03-30 |
Janssen Pharmaceutica N.V. |
Inhibitors of the interaction between mdm2 and p53
|
EP1657241A1
(en)
|
2004-11-03 |
2006-05-17 |
Schering Aktiengesellschaft |
Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors
|
EP1655297A1
(en)
*
|
2004-11-03 |
2006-05-10 |
Schering Aktiengesellschaft |
Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
|
US7906533B2
(en)
|
2004-11-03 |
2011-03-15 |
Bayer Schering Pharma Ag |
Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
|
EP1655295A1
(en)
*
|
2004-11-03 |
2006-05-10 |
Schering Aktiengesellschaft |
Anthranilamide pyridinureas as VEGF receptor kinase inhibitors
|
EP1812392B1
(en)
|
2004-11-05 |
2008-07-09 |
F.Hoffmann-La Roche Ag |
Process for preparation of isonicotinic acid derivatives
|
US8258145B2
(en)
|
2005-01-03 |
2012-09-04 |
Myrexis, Inc. |
Method of treating brain cancer
|
DE602006016564D1
(de)
*
|
2005-03-03 |
2010-10-14 |
Santen Pharmaceutical Co Ltd |
Neue cyclische verbindung mit chinolylalkylthiogruppe
|
PT1863818E
(pt)
|
2005-03-23 |
2010-04-09 |
Hoffmann La Roche |
Derivados de acetilenil-pirazolo-pirimidina como antagonistas de mglur2
|
US7906511B2
(en)
|
2005-03-31 |
2011-03-15 |
Santen Pharmaceutical Co., Ltd. |
Cyclic compound having pyrimidinylalkylthio group
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
AU2006298829B2
(en)
|
2005-09-27 |
2011-03-03 |
F. Hoffmann-La Roche Ag |
Oxadiazolyl pyrazolo-pyrimidines as mGluR2 antagonists
|
GT200600430A
(es)
|
2005-09-27 |
2007-05-21 |
|
Compuestos de carboxiamina y metodos de uso de los mismos
|
US8247556B2
(en)
*
|
2005-10-21 |
2012-08-21 |
Amgen Inc. |
Method for preparing 6-substituted-7-aza-indoles
|
NO20220050A1
(no)
|
2005-11-21 |
2008-08-12 |
Novartis Ag |
Neuroendokrin tumorbehandling
|
EP1955697B1
(en)
*
|
2005-11-30 |
2012-05-02 |
Astellas Pharma Inc. |
2-aminobenzamide derivatives as vanilloid receptor 1 (vr1) inhibitors useful for the treatment of pain or bladder function disorder
|
JP5162574B2
(ja)
|
2006-03-22 |
2013-03-13 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
Mdm2及びp53間の相互作用のインヒビターとしての環式アルキルアミン誘導体
|
CA2644643C
(en)
|
2006-03-22 |
2015-05-19 |
Janssen Pharmaceutica N.V. |
Inhibitors of the interaction between mdm2 and p53
|
WO2007124252A2
(en)
|
2006-04-05 |
2007-11-01 |
Novartis Ag |
Combinations of therapeutic agents for treating cancer
|
EP2272511A1
(en)
|
2006-05-09 |
2011-01-12 |
Novartis AG |
Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
|
GB0612721D0
(en)
|
2006-06-27 |
2006-08-09 |
Novartis Ag |
Organic compounds
|
JP2010504933A
(ja)
|
2006-09-29 |
2010-02-18 |
ノバルティス アーゲー |
Pi3k脂質キナーゼ阻害剤としてのピラゾロピリミジン
|
WO2008077809A1
(en)
*
|
2006-12-22 |
2008-07-03 |
F. Hoffmann-La Roche Ag |
Process for the manufacture of 7-oxa-bicyclo derivatives
|
US8063034B2
(en)
|
2007-01-29 |
2011-11-22 |
Santen Pharmaceutical Co., Ltd. |
Oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity
|
KR20090110913A
(ko)
|
2007-02-15 |
2009-10-23 |
노파르티스 아게 |
Lbh589와 암을 치료하기 위한 다른 치료제와의 조합물
|
EP1975166A1
(en)
*
|
2007-03-30 |
2008-10-01 |
Bayer Schering Pharma AG |
Synthesis of anthranilamides
|
ES2534899T3
(es)
*
|
2007-08-06 |
2015-04-30 |
Janssen Pharmaceutica, N.V. |
Fenilendiaminas sustituidas como inhibidores de la interacción entre MDM2 y p53
|
NZ588069A
(en)
|
2008-03-26 |
2012-06-29 |
Novartis Ag |
Hydroxamate-based inhibitors of deacetylases b
|
TW201010702A
(en)
|
2008-08-27 |
2010-03-16 |
Leo Pharma As |
Novel VEGF-2 receptor and protein tyrosine kinase inhibitors and pharmaceutical use thereof
|
WO2010043050A1
(en)
|
2008-10-16 |
2010-04-22 |
Celator Pharmaceuticals Corporation |
Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab
|
AR074694A1
(es)
|
2008-12-18 |
2011-02-02 |
Novartis Ag |
Sal de hemifumarato del acido 1-(4-{1-[(e)-4-ciclohexil-3-trifluoro-metil-benciloxi-imino]-etil}-2-etil-bencil)-azetidin-3-carboxilico, y otras formas cristalinas de la misma.
|
CA2746764A1
(en)
|
2008-12-18 |
2010-06-24 |
Novartis Ag |
New polymorphic form of 1- (4- { l- [ (e) -4-cyclohexyl--3-trifluoromethyl-benzyloxyimino] -ethyl) -2-ethyl-benzy l) -azetidine-3-carboxylic
|
ES2478842T3
(es)
|
2008-12-18 |
2014-07-23 |
Novartis Ag |
Sal clorhidrato del ácido 1-(4-(1-((E)-4-ciclohexil-3-trifluorometil-benziloxiimino)-etil)-2-etil-benzil)-azetidina-3-carboxílico
|
EP2391366B1
(en)
|
2009-01-29 |
2012-11-28 |
Novartis AG |
Substituted benzimidazoles for the treatment of astrocytomas
|
US8541442B2
(en)
|
2009-02-04 |
2013-09-24 |
Janssen Pharmaceutica N.V. |
Indole derivatives as anticancer agents
|
AU2010264698C1
(en)
|
2009-06-26 |
2013-05-16 |
Novartis Ag |
1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of CYP 17
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
BR112012003262A8
(pt)
|
2009-08-12 |
2016-05-17 |
Novartis Ag |
compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
|
WO2011022439A1
(en)
|
2009-08-17 |
2011-02-24 |
Intellikine, Inc. |
Heterocyclic compounds and uses thereof
|
EP2467383A1
(en)
|
2009-08-20 |
2012-06-27 |
Novartis AG |
Heterocyclic oxime compounds
|
US20120149661A1
(en)
|
2009-08-26 |
2012-06-14 |
Novartis Ag |
Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
|
JP2013504543A
(ja)
|
2009-09-10 |
2013-02-07 |
ノバルティス アーゲー |
二環ヘテロアリール類のエーテル誘導体
|
JP5466767B2
(ja)
|
2009-11-04 |
2014-04-09 |
ノバルティス アーゲー |
Mek阻害剤として有用なヘテロ環式スルホンアミド誘導体
|
JP2013512215A
(ja)
|
2009-11-25 |
2013-04-11 |
ノバルティス アーゲー |
二環式ヘテロアリールのベンゼン縮合6員酸素含有ヘテロ環誘導体
|
US8614239B2
(en)
|
2009-12-08 |
2013-12-24 |
Novartis Ag |
Heterocyclic sulfonamide derivatives
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
CU24130B1
(es)
|
2009-12-22 |
2015-09-29 |
Novartis Ag |
Isoquinolinonas y quinazolinonas sustituidas
|
CN102947274A
(zh)
|
2010-06-17 |
2013-02-27 |
诺瓦提斯公司 |
联苯基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物
|
WO2011157793A1
(en)
|
2010-06-17 |
2011-12-22 |
Novartis Ag |
Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
|
CA2841142C
(en)
|
2010-06-23 |
2020-12-15 |
Ryan D. Morin |
Biomarkers for non-hodgkin lymphomas and uses thereof
|
US9175331B2
(en)
|
2010-09-10 |
2015-11-03 |
Epizyme, Inc. |
Inhibitors of human EZH2, and methods of use thereof
|
EP2614369B1
(en)
|
2010-09-10 |
2016-02-03 |
Epizyme, Inc. |
Method for determining the suitability of inhibitors of human ezh2 in treatment
|
US8946260B2
(en)
|
2010-09-16 |
2015-02-03 |
Novartis Ag |
17α-hydroxylase/C17,20-lyase inhibitors
|
US20130324526A1
(en)
|
2011-02-10 |
2013-12-05 |
Novartis Ag |
[1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
JP5808826B2
(ja)
|
2011-02-23 |
2015-11-10 |
インテリカイン, エルエルシー |
複素環化合物およびその使用
|
WO2012118812A2
(en)
|
2011-02-28 |
2012-09-07 |
Epizyme, Inc. |
Substituted 6,5-fused bicyclic heteroaryl compounds
|
US20130338152A1
(en)
|
2011-03-08 |
2013-12-19 |
Irm Llc |
Fluorophenyl bicyclic heteroaryl compounds
|
JO3438B1
(ar)
|
2011-04-13 |
2019-10-20 |
Epizyme Inc |
مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
|
TWI598336B
(zh)
|
2011-04-13 |
2017-09-11 |
雅酶股份有限公司 |
經取代之苯化合物
|
AU2012249421B9
(en)
|
2011-04-28 |
2015-10-22 |
Novartis Ag |
17alpha-hydroxylase/C17,20-lyase inhibitors
|
KR20140034898A
(ko)
|
2011-06-09 |
2014-03-20 |
노파르티스 아게 |
헤테로시클릭 술폰아미드 유도체
|
EP2721008B1
(en)
|
2011-06-20 |
2015-04-29 |
Novartis AG |
Hydroxy substituted isoquinolinone derivatives as p53 (mdm2 or mdm4) inhibitors
|
US8859586B2
(en)
|
2011-06-20 |
2014-10-14 |
Novartis Ag |
Cyclohexyl isoquinolinone compounds
|
JP5957526B2
(ja)
|
2011-09-15 |
2016-07-27 |
ノバルティス アーゲー |
チロシンキナーゼとしての6−置換3−(キノリン−6−イルチオ)−[1,2,4]トリアゾロ[4,3−a]ピラジン
|
US8969341B2
(en)
|
2011-11-29 |
2015-03-03 |
Novartis Ag |
Pyrazolopyrrolidine compounds
|
US9126980B2
(en)
|
2011-12-23 |
2015-09-08 |
Novartis Ag |
Compounds for inhibiting the interaction of BCL2 with binding partners
|
US20140350014A1
(en)
|
2011-12-23 |
2014-11-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
WO2013096055A1
(en)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
BR112014015322A2
(pt)
|
2011-12-23 |
2017-06-13 |
Novartis Ag |
compostos e composições para inibir a interação de bcl2 com parceiros de ligação
|
KR20140107574A
(ko)
|
2011-12-23 |
2014-09-04 |
노파르티스 아게 |
Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물
|
CN102603729A
(zh)
*
|
2012-01-12 |
2012-07-25 |
贵州大学 |
N-(2-(取代苯并噻唑-2-氨基甲酰基)-取代苯基)吡啶甲酰胺类衍生物
|
JO3357B1
(ar)
|
2012-01-26 |
2019-03-13 |
Novartis Ag |
مركبات إيميدازوبيروليدينون
|
WO2013138753A1
(en)
|
2012-03-16 |
2013-09-19 |
Fox Chase Chemical Diversity Center, Inc. |
Prodrugs of riluzole and their method of use
|
US20150297604A1
(en)
|
2012-04-03 |
2015-10-22 |
Novartis Ag |
Combination Products with Tyrosine Kinase Inhibitors and their Use
|
CN108358899B
(zh)
|
2012-04-13 |
2021-07-27 |
Epizyme股份有限公司 |
人类组蛋白甲基转移酶ezh2抑制剂的盐形式
|
US9365576B2
(en)
|
2012-05-24 |
2016-06-14 |
Novartis Ag |
Pyrrolopyrrolidinone compounds
|
US9006242B2
(en)
|
2012-10-15 |
2015-04-14 |
Epizyme, Inc. |
Substituted benzene compounds
|
EP2948453B1
(en)
|
2013-01-22 |
2017-08-02 |
Novartis AG |
Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
|
US9403827B2
(en)
|
2013-01-22 |
2016-08-02 |
Novartis Ag |
Substituted purinone compounds
|
WO2014151147A1
(en)
|
2013-03-15 |
2014-09-25 |
Intellikine, Llc |
Combination of kinase inhibitors and uses thereof
|
CN103130696B
(zh)
*
|
2013-03-21 |
2014-06-11 |
山东大学 |
邻氨基苯甲酰胺类化合物及其制备方法与应用
|
WO2014155268A2
(en)
|
2013-03-25 |
2014-10-02 |
Novartis Ag |
Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
|
WO2015022664A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
WO2015022663A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
CN103405434A
(zh)
*
|
2013-08-22 |
2013-11-27 |
中国药科大学 |
Vegfr-2抑制剂及其用途
|
SG11201602269QA
(en)
|
2013-10-16 |
2016-04-28 |
Epizyme Inc |
Hydrochloride salt form for ezh2 inhibition
|
CN104163794A
(zh)
*
|
2013-10-17 |
2014-11-26 |
中国药科大学 |
2-氨基芳环类血管内皮生长因子受体(vegfr)抑制剂及其制备方法和用途
|
WO2015084804A1
(en)
|
2013-12-03 |
2015-06-11 |
Novartis Ag |
Combination of mdm2 inhibitor and braf inhibitor and their use
|
ES2831416T3
(es)
|
2014-07-31 |
2021-06-08 |
Novartis Ag |
Terapia de combinación de un inhibidor de MET y un inhibidor de EGFR
|
CA3079076A1
(en)
|
2017-10-18 |
2019-04-25 |
Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus |
Methods and compounds for improved immune cell therapy
|
US11602534B2
(en)
|
2017-12-21 |
2023-03-14 |
Hefei Institutes Of Physical Science, Chinese Academy Of Sciences |
Pyrimidine derivative kinase inhibitors
|
US20220395553A1
(en)
|
2019-11-14 |
2022-12-15 |
Cohbar, Inc. |
Cxcr4 antagonist peptides
|
WO2021138540A1
(en)
|
2020-01-03 |
2021-07-08 |
Berg Llc |
Polycyclic amides as ube2k modulators for treating cancer
|
WO2022222890A1
(en)
*
|
2021-04-19 |
2022-10-27 |
Shanghai Yao Yuan Biotechnology Co., Ltd. |
Benzothiazole and quinoline derivatives for use in treating kawasaki disease
|